StubbingsJKongSX:Pharmacoeconomics and outcomes research in the era of disease management. J Pharm Pract8:139–142,1995.
2.
Proceedings, Academy Managed Care Pharm. Educational Conference, Boston, October 21–23, 1994, Stephen J. Coons, Assessing Outcomes of Disease Management Prog QOL and Care.
3.
JewellMASchillingtonASDempseyCL: An Orientation to Outcomes Management and Disease State Management for Pharmaceutical Representatives. Library of Congress, Washington, DC, 1995.
4.
TownsendRJ:Post-marketing drug research and development. Drug Intell Clin Pharm21:134–136,1987.
5.
KongSXStubbingsJ:Assessing the economic value of pharmaceutical products and services. J Pharm Pract8:143–155,1995.
6.
KongSXSchumockGT: Principle of pharmacoeconomics. Keeposted, March 5–10, 1995.
7.
DetskeyAS:Guidelines for economic analysis of pharmaceutical products: A draft document for Ontario and Canada. PharmacoEconomics3:354–361,1993.
8.
SchwartzJS: Implementing disease state management for benign prostatic hyperplasia: An overview of pharmacoeconomic study design. Proceedings, Academy Managed Care Pharm, 7th Annual Meeting, Toronto, Ontario, May 18, 1995.
9.
LindleyCMHirschJDO'NeillCV:Quality of life consequences of chemotherapy: Induced emesis. Quality Life Res1:331–340,1992.